Key statistics dashboard for Opus Genetics, Inc. (IRD). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
Stock Data
| Price | $5.41 |
| Market Cap | $447M |
| Beta | 0.52 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -4.26 |
| Price / Book | -39.78 |
| P/S | 45.32 |
| P/FCF | -10.98 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.87% |
| EBIT Margin | -1064.96% |
| EBITDA Margin | -1064.56% |
| Operating Margin | -513.47% |
| Net Margin | -1091.82% |
Financial Health
| Current Ratio | 12.19 |
| Quick Ratio | 12.19 |
| Cash Ratio | 11.68 |
| Debt / Equity | -2.69 |
| Debt / Assets | 37.57% |
| Interest Coverage | -19.11 |
Per-Share Data
| Revenue per share | 0.10 |
| Book Value per share | -0.14 |
| Cash per share | 0.93 |
| FCF per share | -0.43 |
| Tangible Book Value per share | -0.14 |
| Dividend per share | 0.00 |
Related companies: ABOS · AGEN · ALEC · CGTX · HURA · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of IRD: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks